Production (Stage)
United Therapeutics Corporation
UTHR
$307.65
-$1.07-0.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 322.20M | 301.30M | 309.10M | 278.10M | 306.60M |
| Total Depreciation and Amortization | 19.80M | 19.70M | 19.10M | 18.70M | 15.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.20M | 24.40M | 36.00M | 44.20M | 15.10M |
| Change in Net Operating Assets | 78.00M | -4.20M | 13.00M | -108.80M | 39.80M |
| Cash from Operations | 461.20M | 341.20M | 377.20M | 232.20M | 376.50M |
| Capital Expenditure | -74.90M | -86.70M | -76.50M | -45.10M | -38.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.80M | -36.50M | -38.40M | -34.90M | 773.50M |
| Cash from Investing | -164.70M | -123.20M | -114.90M | -80.00M | 735.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00M | -100.00M | -100.00M | -100.00M | -100.00M |
| Issuance of Common Stock | 21.50M | 25.60M | 36.30M | 52.10M | 46.10M |
| Repurchase of Common Stock | -15.30M | -300.00K | -400.00K | -100.00K | -1.01B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -2.70M |
| Cash from Financing | -93.80M | -74.70M | -64.10M | -48.00M | -1.07B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 202.70M | 143.30M | 198.20M | 104.20M | 43.80M |